



Press release

SHL Telemedicine's SmartHeart® technology shows remarkable effects in Mayo Clinic and Imperial College London trials

Promising outcomes indicate significant reductions in emergency visits and hospital readmissions, alongside reductions in healthcare utilization costs relating to post-MI patient treatment.

Tel Aviv / Zurich / New York, 26 September 2023 – SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("**SHL**" or the "**Company**"), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce the initial results from the Mayo Clinic HELP-MI and the Imperial College London TELE-ACS trials, presented at the Vulnerable Plaque and Patient Meeting (VPM) 2023 (as previously announced).

The initial findings from both trials, which focus on the application of SHL's patented and FDA cleared SmartHeart® 12-lead ECG technology for monitoring of post-MI (heart attack) patients at home, have been nothing short of remarkable.

Key highlights from the presentation of the initial results include:

- A staggering decrease of - 27.5% in emergency room visits in the TELE-ACS trial¹.
- Moreover, hospital readmission rates plummeted by -55% in the TELE-ACS trial¹.
- In the HELP-ME trial, cardiovascular-driven emergency department visits for patients using the SmartHeart® device were reduced to an astonishing 0 (zero)².
- Cardiovascular driven rehospitalization was also at 0 (zero)² for patients using the device in the HELP-ME trial.
- The presentation at the conference noted that the HELP-ME trial demonstrated the potential of SHL's system be successfully replicated in the US medical system, emphasizing its capability to reduce non-indicated cardiovascular emergency department visits and hospitalizations while improving early recognition of serious cardiovascular presentations.

Erez Nachtomy, CEO of SHL Telemedicine, commented, "The initial results from the HELP-MI and TELE-ACS trials have surpassed our expectations. We are extremely confident in the potential of our SmartHeart® technology, and these findings further validate its efficacy in post-MI patient care. We are looking forward to the continued positive impact our technology will have on telemedicine and remote patient care."

Presentations of the trials from the VPM 2023 conference are available at:

<https://www.millbrook-events.co.uk/VPM2023>

¹ Telemedicine group vs. control standard care group at 3 months follow-up

² Telemedicine group compliant users vs. control group



About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200). For more information, please visit our website at www.shl-telemedicine.com.

Forward-Looking Statements

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.

For further information please contact:

Fabienne Farner, IRF, Phone : +41 43 244 81 42, farner@irf-reputation.ch